205. Fragile X syndrome related disease Clinical trials / Disease details
Clinical trials : 5 / Drugs : 7 - (DrugBank : 5) / Drug target genes : 22 - Drug target pathways : 25
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05233579 (ClinicalTrials.gov) | June 25, 2021 | 20/10/2021 | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS to Find Biomarkers | Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis) | Dietary Supplement: Sulforaphane | University of California, Davis | NULL | Recruiting | 50 Years | 85 Years | All | 15 | N/A | United States |